Jorge Conde
@JorgeCondeBio
GP at @a16z investing in bio + health | former biotech founder + operator (CEO, CFO, CSO, CPO) 🧬🧫🧪 | made in Miami 🇺🇸 🇵🇪 🇨🇺
1/ 🦸♂️ The explosion of new modalities (or types) of medicines gives us new superpowers to tackle disease. As our arsenal expands, how will patients, physicians & markets choose the right tool? a16z.com/outclassed-the…
Thrilled to back @miramurati and the world-class team behind ~ every major recent AI research and product breakthrough. RL (PPO, TRPO, GAE), reasoning, multimodal, Character, and of course ChatGPT! No one is better positioned to advance the frontier. Excited to see the future…
Thinking Machines Lab exists to empower humanity through advancing collaborative general intelligence. We're building multimodal AI that works with how you naturally interact with the world - through conversation, through sight, through the messy way we collaborate. We're…
🚨NYC folks! Come join us for a fireside chat (and networking session) on the next frontiers of AIxBio between @nvidia 's @anthonycosta and @Dyno_Tx's @ekelsic on June 3rd as a part of #NYTechWeek (info linked below👇) RSVP early as space is filling up fast.
A 9 month-old baby boy with a fatal genetic disease was healed with the 1st-ever personalized n-of-1 gene-editing therapy. We live in an era of medical marvels.
New @a16z podcast: Arif Nathoo, co-founder & CEO of @KomodoHealth. @ArifNathooMD shares w/ @JorgeCondeBio & me how Komodo built the most comprehensive healthcare data map: 🗺️ [0:37] Building Komodo from scratch: the vision behind a comprehensive healthcare map 🇺🇸 [1:31] What's…
TOMORROW: Join us at this year’s #ASGCT25 Dyno Symposium! Dyno CEO & Cofounder Eric Kelsic will share data on leading-edge AAV capsids, the frontier AI models behind their design, and how Dyno supports partners rapidly advancing next-generation gene therapies into the clinic.
Yes we need to control costs and reduce healthcare spend. But when it comes to drug pricing policy, beware of unwanted side effects: “Most Favored Nation” may mostly disfavor innovation. 🇺🇸 💊🧬
Be sure to catch Dyno at #SynBioBeta2025 next week! Our CEO & Cofounder Eric Kelsic will be giving a talk and speaking on a panel highlighting what is possible at the intersection of AI and gene therapy, and what this means for the future of human health.
“Noventa minuti en el Bernabéu son molto longo.” wsj.com/sports/soccer/…
Don’t miss our co-founder @samsinai’s talk at #GTC2025! Sam will share Dyno’s latest progress on LEAP—our technology bridging foundation models and therapeutic impact—and demo DynoFold, a new AI model powered by @NVIDIAAI that efficiently predicts protein dynamics directly from…
We have a position open for an ML Scientist role to take part in one of the most ambitious undertakings in AI-driven protein design. If you have worked on frontier models (in or outside biology), or protein design, join us and find out. dynotx.com/careers/?gh_ji…
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis…
Congratulations to IDRx and @GSK for joining forces. This acquisition represents a pivotal moment in the journey to address a significant unmet need for the treatment of gastrointestinal stromal tumors (GIST). idrx.com/resources/gsk-…
AI + biomanufacturing: @novonordisk licenses @AsimovBio’s CHO Edge System for biologics production.
We’re proud to share that our CHO Edge System has been licensed by Novo Nordisk, a global leader in healthcare innovation. Forward-thinking companies like Novo Nordisk recognize the importance of accessing cutting-edge technologies to advance therapeutic development. We’re…